ATE403726T1 - Cytokin-proteinfamilie - Google Patents

Cytokin-proteinfamilie

Info

Publication number
ATE403726T1
ATE403726T1 AT02764322T AT02764322T ATE403726T1 AT E403726 T1 ATE403726 T1 AT E403726T1 AT 02764322 T AT02764322 T AT 02764322T AT 02764322 T AT02764322 T AT 02764322T AT E403726 T1 ATE403726 T1 AT E403726T1
Authority
AT
Austria
Prior art keywords
protein family
cytokine protein
amino acid
seq
acid residues
Prior art date
Application number
AT02764322T
Other languages
English (en)
Inventor
Paul Sheppard
Brain Fox
Kevin Klucher
David W Taft
Wayne Kindsvogel
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/895,834 external-priority patent/US6927040B2/en
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of ATE403726T1 publication Critical patent/ATE403726T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
AT02764322T 2001-04-20 2002-04-19 Cytokin-proteinfamilie ATE403726T1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US28542401P 2001-04-20 2001-04-20
US28540801P 2001-04-20 2001-04-20
US28648201P 2001-04-25 2001-04-25
US09/895,834 US6927040B2 (en) 2000-06-30 2001-06-29 Interferon-like protein Zcyto21
US34110501P 2001-10-22 2001-10-22
US34105001P 2001-10-22 2001-10-22

Publications (1)

Publication Number Publication Date
ATE403726T1 true ATE403726T1 (de) 2008-08-15

Family

ID=27559579

Family Applications (2)

Application Number Title Priority Date Filing Date
AT08153475T ATE482272T1 (de) 2001-04-20 2002-04-19 Zytokinproteinfamilie
AT02764322T ATE403726T1 (de) 2001-04-20 2002-04-19 Cytokin-proteinfamilie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT08153475T ATE482272T1 (de) 2001-04-20 2002-04-19 Zytokinproteinfamilie

Country Status (12)

Country Link
EP (2) EP1501936B1 (de)
JP (1) JP4350950B2 (de)
CN (2) CN101531715A (de)
AT (2) ATE482272T1 (de)
AU (1) AU2002307510A1 (de)
BR (1) BR0205083A (de)
CA (1) CA2441958C (de)
DE (2) DE60237791D1 (de)
DK (1) DK1501936T3 (de)
ES (1) ES2311622T3 (de)
RU (1) RU2321594C2 (de)
WO (1) WO2002086087A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE445701T1 (de) 2000-11-28 2009-10-15 Zymogenetics L L C Zytokine rezeptor zcytor19
US7033787B2 (en) * 2001-12-21 2006-04-25 Ludwig Institute For Cancer Research Isolated cytokine receptor LICR-2
WO2003089603A2 (en) * 2002-04-19 2003-10-30 Zymogenetics, Inc. Cytokine receptor
US7135170B2 (en) * 2002-10-23 2006-11-14 Zymogenetics, Inc. Methods for treating viral infection using IL-28 and IL-29
CA2534907C (en) 2003-08-07 2014-04-29 Zymogenetics, Inc. Homogeneous preparations of il-28 and il-29
AU2005231476B2 (en) * 2004-04-02 2011-09-01 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
JP2008508310A (ja) 2004-07-29 2008-03-21 ザイモジェネティクス， インコーポレイテッド がんおよび自己免疫障害を治療するためのｉｌ−２８およびｉｌ−２９の使用法
CA2616004A1 (en) * 2005-07-20 2007-02-01 Zymogenetics, Inc. Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders
US9051369B2 (en) 2007-09-20 2015-06-09 Commonwealth Scientific And Industrial Research Organisation Avian cytokines and genetic sequences encoding same
JP5821198B2 (ja) * 2011-01-27 2015-11-24 富士レビオ株式会社 抗ｉｌ２８ｂ抗体及びこれを用いたｉｌ２８ｂの測定方法
FR2975185A1 (fr) * 2011-05-12 2012-11-16 Univ Claude Bernard Lyon Procede de determination in vitro de la presence d'une sclerose en plaques
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
CN110894525A (zh) * 2018-09-12 2020-03-20 贵州大学 从江香猪IFN-λ1基因的检测方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK170236B1 (da) * 1980-01-08 1995-07-10 Biogen Inc Rekombinante DNA-molekyler, fremgangsmåde til fremstilling af et polypeptid af IFN-alfa typen og fremgangsmåde til udvælgelse af DNA-sekvenser, der koder for polypeptider af IFN-alfa typen
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
DE69824719T2 (de) * 1997-04-25 2005-06-30 Zymogenetics, Inc., Seattle Cytokinähnlicher faktor-7 aus säugetieren
US5924404A (en) 1997-10-24 1999-07-20 Brunswick Corporation Cylinder-specific spark ignition control system for direct fuel injected two-stroke engine
BR9914777A (pt) 1998-10-26 2001-07-03 Ludwig Inst Cancer Res Moléculas isoladas de ácido nucléico que codificam os fatores induzìveis por células t (tifs), as proteìnas codificadas e os usos das mesmas
CA2354536A1 (en) 1998-12-18 2000-06-29 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
AU3891600A (en) * 1999-03-18 2000-10-04 Zymogenetics Inc. Murine interferon-alpha named also zcyto13
US6391948B1 (en) 1999-12-14 2002-05-21 3M Innovative Properties Company Triazine compounds and use thereof
JP2004535795A (ja) * 2001-05-10 2004-12-02 イミュネックス・コーポレーション サイトカインポリペプチド群
WO2003066002A2 (en) * 2002-02-08 2003-08-14 University Of Medicine And Dentistry Of New Jersey IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION

Also Published As

Publication number Publication date
CA2441958C (en) 2012-01-17
EP1942187B1 (de) 2010-09-22
DK1501936T3 (da) 2008-12-08
BR0205083A (pt) 2004-07-20
CN1620510A (zh) 2005-05-25
JP2005506052A (ja) 2005-03-03
EP1501936B1 (de) 2008-08-06
ATE482272T1 (de) 2010-10-15
RU2003133748A (ru) 2005-05-10
RU2321594C2 (ru) 2008-04-10
AU2002307510A1 (en) 2002-11-05
ES2311622T3 (es) 2009-02-16
WO2002086087A3 (en) 2004-11-18
WO2002086087A2 (en) 2002-10-31
CA2441958A1 (en) 2002-10-31
EP1942187A1 (de) 2008-07-09
JP4350950B2 (ja) 2009-10-28
DE60237791D1 (de) 2010-11-04
EP1501936A2 (de) 2005-02-02
DE60228136D1 (de) 2008-09-18
CN100482684C (zh) 2009-04-29
EP1501936A4 (de) 2005-07-20
CN101531715A (zh) 2009-09-16

Similar Documents

Publication Publication Date Title
ATE536406T1 (de) Neuartiger zytokin-zcytor17-ligand
DE69634726D1 (de) Menschliche ctla-8 und verwendung von ctla-8 ähnlichen proteinen
ATE403726T1 (de) Cytokin-proteinfamilie
DE60135393D1 (de) Allelische Variante des Interferon-ähnlichen Proteins Zcyto21
ATE269902T1 (de) Cytokinähnliches polypeptid-10 aus säugetieren
ATE495247T1 (de) Chromoprotein und fluoroproteine
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
ATE409747T1 (de) Mit wt1 interagierendes protein, wtip

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1501936

Country of ref document: EP